您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2017, Vol. 55 ›› Issue (6): 119-123.doi: 10.6040/j.issn.1671-7554.0.2017.338

• • 上一篇    下一篇

中性粒细胞计数与非酒精性脂肪肝关联性的前瞻性队列研究

柳晓涓1,2,蒋正1,2,康凤玲1,2,周苗1,2,林伟强1,2,薛付忠1,2   

  1. 1.山东大学公共卫生学院生物统计学系, 山东 济南 250012;2.山东大学齐鲁生物医学大数据研究中心, 山东 济南 250012
  • 收稿日期:2017-04-18 出版日期:2017-06-10 发布日期:2017-06-10
  • 通讯作者: 薛付忠. E-mail:xuefzh@sdu.edu.cn E-mail:xuefzh@sdu.edu.cn
  • 基金资助:
    国家自然科学基金(81273177);国家自然科学基金青年基金(81400072);山东省自然科学基金(2013HQ047)

Association between neutrophil count and nonalcoholic fatty liver disease:a prospective cohort study

LIU Xiaojuan1,2, JIANG Zheng1,2, KANG Fengling1,2, ZHOU Miao1,2, LIN Weiqiang1,2, XUE Fuzhong1,2   

  1. 1. Department of Biostatistics, School of Public Health, Shandong University, Jinan 250012, Shandong, China;
    2. Cheeloo Research Center for Biomedical Big Data, Shandong University, Jinan 250012, Shandong, China
  • Received:2017-04-18 Online:2017-06-10 Published:2017-06-10

PDF (PC)

274

摘要： 目的 探讨中性粒细胞计数与非酒精性脂肪肝(NAFLD)的关联性。 方法 基于大规模健康管理队列,针对队列基线中无NAFLD的15 463例健康体检对象随访,平均随访时间2.54年,随访结局为发生NAFLD;将基线中性粒细胞计数根据四分位数由低到高划分为4个组段(Q1、Q2、Q3、Q4);采用多元Cox回归计算中性粒细胞计数与NAFLD关联性的相对危险度(HR)。 结果 随访期间3 846人被诊断为NAFLD。Cox结果显示,以Q1为参照,在调整年龄、性别后,中性粒细胞计数的Q2、Q3、Q4三个组段的HR(95%CI)分别为1.265(1.057,1.514)、1.446(1.214,1.724)、1.605(1.350,1.907),上述基础上再调整谷丙转氨酶和γ-谷酰胺转酞酶后,Q2、Q3、Q4三个组段的HR(95%CI)分别为1.264(1.056,1.512)、1.434(1.202,1.710)、1.582(1.330,1.882),进一步调整血脂四项、空腹血糖、体质量指数(BMI)和高血压后,HR(95%CI)分别为1.181(0.986,1.415)、1.189(0.995,1.420)、1.226(1.026,1.464)。 结论 中性粒细胞计数是NAFLD发病的独立危险因素。

关键词: 中性粒细胞计数, 队列研究, Cox回归, 健康管理人群, 非酒精性脂肪肝

Abstract: Objective To explore the longitudinal association between neutrophil count and nonalcoholic fatty liver disease(NAFLD). Methods The cohort consisted of 15 463 non-NAFLD individuals at baseline who were followed for the incident of NAFLD. Cox model was applied to calculate the hazard ratio(HR)and its 95% confidence intervals(95%CI)of quantiles(Q1, Q2, Q3 and Q4)of neutrophil count predicting NAFLD. Results During the follow-up, 3 846 new cases of NAFLD occurred. With Q1 as reference group, after adjusting for age and gender, the HRs(95%CI)of Q2, Q3, and Q4 were 1.265(1.057,1.514), 1.446(1.214,1.724)and 1.605(1.350,1.907), respectively. On the basis of previous model, alanine aminotransferase and gamma glutamyltransferase were added into the model, and the HRs(95%CI)of Q2, Q3, and Q4 were 1.264(1.056,1.512), 1.434(1.202,1.710)and 1.582(1.330,1.882), respectively. After adding BMI, systolic pressure, diastolic pressure, fasting glucose and blood lipids into the model, the HRs(95%CI)were 1.181(0.986,1.415), 1.189(0.995,1.420)and 1.226(1.026,1.464), respectively. Conclusion Neutrophil count is an independent risk factor for the incidence of NAFLD.

Key words: Neutrophil count, Cox regression, Health management population, Nonalcoholic fatty liver disease, Cohort study

中图分类号: 

  • R575.5
[1] Malhotra N, Beaton MD. Management of non-alcoholic fatty liver disease in 2015[J]. World J Hepatol, 2015, 7(30): 2962-2967.
[2] Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease[J]. Atherosclerosis, 2015, 239(1): 192-202.
[3] Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China[J]. J Gastroenterol Hepatol, 2013, 28(Suppl 1): 11-17.
[4] Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China[J]. J Hepatol, 2009, 50(1): 204-210.
[5] Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China[J]. J Hepatol, 2005, 43(3): 508-514.
[6] Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease[J]. N Engl J Med, 2010, 363(14): 1341-1350.
[7] Choi SY, Kim D, Kim HJ, et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans[J]. Am J Gastroenterol, 2009, 104(8): 1953-1960.
[8] Lizardi-Cervera J, Aguilar-Zapata D. Nonalcoholic fatty liver disease and its association with cardiovascular disease[J]. Ann Hepatol, 2009, 8(Suppl 1): S40-S43.
[9] Park HE, Kwak MS, Kim D, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification development: a longitudinal study[J]. J Clin Endocrinol Metab, 2016, 101(8): 3134-3143.
[10] Li Z, Xue J, Chen P, et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: a meta-analysis of published studies[J]. J Gastroenterol Hepatol, 2014, 29(1): 42-51.
[11] Chitturi S, Farrell GC, Hashimoto E, et al. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines[J]. J Gastroenterol Hepatol, 2007, 22(6): 778-787.
[12] Fan JG, Jia JD, Li YM, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010:(published in Chinese on Chinese Journal of Hepatology, 2010; 18:163-166)[J]. J Dig Dis, 2011, 12(1): 38-44.
[13] 申振伟, 季晓康, 王庆莲, 等. 非酒精性脂肪肝与慢性肾脏病关系的回顾性队列研究[J]. 山东大学学报(医学版), 2016, 54(7): 43-49. SHEN Zhenwei, JI Xiaokang, WANG Qingliang, et al. Association between nonalcoholic fatty liver disease and chronic kidney disease: a retrospective cohort study[J]. Journal of Shandong University(Health Science), 2016, 54(7): 43-49.
[14] Pagano C, Soardo G, Esposito W, et al. Plasma adiponectin is decreased in nonalcoholic fatty liver disease[J]. Eur J Endocrinol, 2005, 152(1): 113-118.
[15] Haukeland JW, Damas JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2[J]. J Hepatol, 2006, 44(6): 1167-1174.
[16] Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J]. Aliment Pharmacol Ther, 2011, 34(3): 274-285.
[17] Lizardi-Cervera J, Chavez-Tapia NC, Pérez-Bautista O, et al. Association among C-reactive protein, fatty liver disease, and cardiovascular risk[J]. Dig Dis Sci, 2007, 52(9): 2375-2379.
[18] Kogiso T, Moriyoshi Y, Shimizu S, et al. High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike Information Criterion scoring system in the general Japanese population[J]. J Gastroenterol, 2009, 44(4): 313-321.
[19] Dogru T, Ercin CN, Erdem G, et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis[J]. Am J Gastroenterol, 2008, 103(12): 3217-3218.
[20] Bahcecioglu IH, Yalniz M, Ataseven H, et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis[J]. Hepatogastroenterology, 2005, 52(65): 1549-1553.
[21] Lee YJ, Lee HR, Shim JY, et al. Relationship between white blood cell count and nonalcoholic fatty liver disease[J]. Dig Liver Dis, 2010, 42(12): 888-894.
[22] Alkhouri N, Morris-Stiff G, Campbell C, et al. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease[J]. Liver Int, 2012, 32(2): 297-302.
[23] Lee BC, Lee J. Cellular and molecular players in adipose tissue inflammation in the development of obesity-induced insulin resistance[J]. Biochim Biophys Acta, 2014, 1842(3): 446-462.
[24] Kaur H, Adams-Huet B, Smith G, et al. Increased neutrophil count in nascent metabolic syndrome[J]. Metab Syndr Relat Disord, 2013, 11(2): 128-131.
[25] Wang JB, Zhang YJ, Guan J, et al. Enhanced syndecan-1 expression on neutrophils in patients with type 2 diabetes mellitus[J]. Acta Diabetologica, 2012, 49(1): 41-46.
[26] Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art[J]. World J Gastroenterol, 2014, 20(37): 13306-13324.
[27] Bi WR, Yang CQ, Shi Q, et al. Large-scale analysis of factors influencing nonalcoholic fatty liver disease and its relationship with liver enzymes[J]. Genet Mol Res, 2014, 13(3): 5880-5891.
[28] Frith J, Day CP, Henderson E, et al. Non-alcoholic fatty liver disease in older people[J]. Gerontology, 2009, 55(6): 607-613.
[29] Zhang T, Zhang C, Zhang Y, et al. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study[J]. Atherosclerosis, 2015, 240(1): 144-148.
[30] Zhang T, Zhang Y, Zhang C, et al. Prediction of metabolic syndrome by non-alcoholic fatty liver disease in northern urban Han Chinese population: a prospective cohort study[J]. PLoS One, 2014, 9(5): e96651. doi: 10.1371/journal.pone.0096651.
[31] Wang S, Zhang C, Zhang G, et al. Association between white blood cell count and non-alcoholic fatty liver disease in urban Han Chinese: a prospective cohort study[J]. BMJ Open, 2016, 6(6): e010342. doi: 10.1136/bmjopen-2015-010342.
[32] Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis[J]. Annu Rev Pathol, 2010, 5: 145-171. doi: 10.1146/annurev-pathol-121808-102132.
[33] Poniachik J, Csendes A, Diaz JC, et al. Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease[J]. Cytokine, 2006, 33(5): 252-257.
[34] Park SH, Kim BI, Yun JW, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men[J]. J Gastroenterol Hepatol, 2004, 19(6): 694-698.
[35] 张莉, 宋海燕, 季光. 非酒精性脂肪肝代谢调控与炎症反应的共同通路[J]. 中华肝脏病杂志, 2011,19(5): 395-397. ZHANG Li, SONG Haiyan, JI Guang. The joint pathway of metabolism and inflammation in nonalcoholic fatty liver disease[J]. Chinese Journal of Hepatology, 2011, 19(5): 395-397.
[36] Botezelli JD, Mora RF, Dalia RA, et al. Exercise counteracts fatty liver disease in rats fed on fructose-rich diet[J]. Lipids Health Dis, 2010, 9: 116. doi: 10.1186/1476-511X-9-116.
[1] 曹瑾,季晓康,孙秀彬,蒋正,薛付忠. γ-谷氨酰转肽酶与高尿酸血症关系的队列分析[J]. 山东大学学报（医学版）, 2017, 55(6): 124-128.
[2] 张光,王广银,吴红彦, 张红玉,王停停,李吉庆,李敏,康凤玲,刘言训,薛付忠. 健康管理人群高脂血症风险预测模型[J]. 山东大学学报（医学版）, 2017, 55(6): 72-76.
[3] 李江冰,宋心红,林海燕,张冬芝,李向一,许艺博,王丽,薛付忠. 健康管理人群缺血性异常心电图的影响因素[J]. 山东大学学报（医学版）, 2017, 55(6): 77-81.
[4] 孙苑潆,杨亚超,曲明苓,陈雁敏,李敏,王淑康,薛付忠,刘云霞. 健康管理人群代谢综合征发病风险预测模型[J]. 山东大学学报（医学版）, 2017, 55(6): 87-92.
[5] 李敏,王春霞,夏冰,朱茜,孙苑潆,王淑康,薛付忠,贾红英. 健康管理人群脑卒中风险预测模型[J]. 山东大学学报（医学版）, 2017, 55(6): 93-97.
[6] 蒋正,申振伟,张光,李润滋,曹瑾,王丽,薛付忠,刘言训. 基于体检人群的非酒精性脂肪肝筛查工具的建立[J]. 山东大学学报（医学版）, 2017, 55(6): 114-118.
[7] 于媛媛,王春霞,苏萍,孙苑潆,薛付忠,刘言训. 健康管理队列白内障发病风险预测模型[J]. 山东大学学报（医学版）, 2017, 55(6): 104-107.
[8] 李向一,孙秀彬,鹿玉莲,申振伟,陈亚飞,唐芳,薛付忠. 子宫肌瘤与乳腺增生关联性的队列研究[J]. 山东大学学报（医学版）, 2016, 54(9): 53-58.
[9] 申振伟,季晓康,王庆莲,李洁,薛付忠,刘静. 非酒精性脂肪肝与慢性肾脏病关系的回顾性队列研究[J]. 山东大学学报（医学版）, 2016, 54(7): 43-49.
[10] 林栋,管庆波. 2型糖尿病男性患者血清睾酮水平低下对非酒精性脂肪肝的影响[J]. 山东大学学报（医学版）, 2016, 54(7): 33-37.
[11] 刘言训, 刘佳, 张涛, 王璐, 薛付忠, 王萍. 基于纵向监测队列的2型糖尿病与甲状腺结节的关联性[J]. 山东大学学报（医学版）, 2015, 53(8): 83-86.
[12] 李少伟, 刘宗正, 刘春霞, 张焱如, 周欢敏. 口服富氢水对小鼠脂肪肝缺血再灌注损伤的保护作用[J]. 山东大学学报（医学版）, 2015, 53(1): 10-15.
[13] 张凌云1，2，赵家军1，金勇君2，李建周2 . 2型糖尿病患者抵抗素基因420 C/G多态性与非酒精性脂肪肝的关系[J]. 山东大学学报(医学版), 2011, 49(7): 1-5.
[14] 章蓉1，2，吴凤芸2，徐贵发1 . 对非酒精性脂肪肝患者生活方式干预的效果评价[J]. 山东大学学报(医学版), 2010, 48(8): 113-116.
[15] 李顺平1，刘婷婷2，陈春辉1，李咏梅2. 济南铁路工人非酒精性脂肪肝病的患病率及影响因素分析[J]. 山东大学学报(医学版), 2010, 48(10): 125-.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发